India denied the patent for Pfizer on tofacitinib (a rheumatoid arthritis drug). The reason cited was the inability of the company to establish a more active therapeutic efficacy than the active compound.
top of page
Search
Recent Posts
See AllGeneral Motors has secured an Indian patent on a hybrid powertrain control system for vehicles. The patent rights are currently assigned...
Taking into consideration the Delhi High court’s order staying the abandonment orders passed by the Trademarks Office, the Registrar of...
The order of the Delhi High Court allows the Competition Commission of India (CCI) to attend to complaints on abuse of dominance of...
bottom of page
Comments